GM 6

Drug Profile

GM 6

Alternative Names: GM6; GM600; GM602; GM603; GM604; GM605; GM606; GM607; GM608; GM609

Latest Information Update: 05 May 2016

Price : $50

At a glance

  • Originator Genervon Biopharmaceuticals
  • Class Antiparkinsonians; Neuroprotectants; Peptides
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase modulators; Apoptosis inhibitors; Bcl-X protein inhibitors; Free radical inhibitors; Insulin receptor modulators; Nervous system modulators; Neurogenesis modulators; Proto oncogene protein c akt modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis; Parkinson's disease; Stroke
  • Phase I Alzheimer's disease; Multiple sclerosis; Spinal cord injuries
  • Preclinical Musculoskeletal disorders
  • Research Huntington's disease

Most Recent Events

  • 03 May 2016 The Committee for Orphan Medicinal Products (COMP) of the EMA issues a positive opinion to grant the orphan drug designation in the EU
  • 03 May 2016 Genervon Biopharmaceuticals plans a phase III trial for Amyotrophic lateral sclerosis in USA
  • 17 Feb 2016 GM 6 is still in phase II trials for Stroke in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top